Trial record 1 of 1 for:    NCT02190721
Previous Study | Return to List | Next Study

A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02190721
Recruitment Status : Completed
First Posted : July 15, 2014
Last Update Posted : April 9, 2018
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Pharmaceutical Industries, Ltd. )

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : April 4, 2017
  Actual Study Completion Date : April 4, 2017
  Certification/Extension First Submitted : April 6, 2018

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 May 18, 2018
June 15, 2018